CME/CE

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.